These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 1978495)

  • 1. Monoamines and schizophrenia.
    Sedvall G
    Acta Psychiatr Scand Suppl; 1990; 358():7-13. PubMed ID: 1978495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent developments in PET scan imaging of neuroreceptors in schizophrenia.
    Sedvall G; Pauli S; Farde L; Karlsson P; Nyberg S; Nordström AL
    Isr J Psychiatry Relat Sci; 1995; 32(1):22-9. PubMed ID: 7622344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine receptors and the dopamine hypothesis of schizophrenia.
    Seeman P
    Synapse; 1987; 1(2):133-52. PubMed ID: 2905529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurochemical and neural mechanisms of positive and negative symptoms in schizophrenia.
    Pickar D; Litman RE; Konicki PE; Wolkowitz OM; Breier A
    Mod Probl Pharmacopsychiatry; 1990; 24():124-51. PubMed ID: 1970851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action.
    Sanyal S; Van Tol HH
    J Psychiatr Res; 1997; 31(2):219-32. PubMed ID: 9278187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia.
    Reynolds GP
    Acta Psychiatr Scand Suppl; 1994; 380():36-40. PubMed ID: 7914046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of remoxipride to the human brain and central D2-dopamine receptor binding examined in vivo by PET.
    Farde L; von Bahr C
    Acta Psychiatr Scand Suppl; 1990; 358():67-71. PubMed ID: 1978494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Transmitter dysfunction in patients with schizophrenia. Significance for cognitive functioning and treatment].
    Glenthøj BY; Mackeprang T; Bille AE; Hemmingsen RP
    Ugeskr Laeger; 1999 Mar; 161(10):1391-8. PubMed ID: 10085745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical findings with new antipsychotic agents: what makes them atypical?
    Jackson DM; Ryan C; Evenden J; Mohell N
    Acta Psychiatr Scand Suppl; 1994; 380():41-8. PubMed ID: 7914047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathology and drug action in schizophrenia: insights from molecular biology.
    Strange PG
    Essays Biochem; 1998; 33():105-16. PubMed ID: 10488445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia.
    Deutch AY; Moghaddam B; Innis RB; Krystal JH; Aghajanian GK; Bunney BS; Charney DS
    Schizophr Res; 1991; 4(2):121-56. PubMed ID: 1674882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The current status of PET scanning with respect to schizophrenia.
    Sedvall G
    Neuropsychopharmacology; 1992 Aug; 7(1):41-54. PubMed ID: 1388021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride.
    Farde L; Wiesel FA; Stone-Elander S; Halldin C; Nordström AL; Hall H; Sedvall G
    Arch Gen Psychiatry; 1990 Mar; 47(3):213-9. PubMed ID: 1968328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroleptic treatment of patients with schizophrenia. Mechanisms of action and clinical significance.
    Wiesel FA
    Br J Psychiatry Suppl; 1994 Apr; (23):65-70. PubMed ID: 7913610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open multicentre study of the treatment of florid schizophrenia with remoxipride.
    McCreadie RG; Morrison D; Eccleston D; Gall RG; Loudon J; Mitchell MJ
    Acta Psychiatr Scand; 1985 Aug; 72(2):139-43. PubMed ID: 2864790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neurochemical circuitry of schizophrenia.
    Carlsson A
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S10-4. PubMed ID: 16508890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D1 and D2 and D3.
    Healy D
    Br J Psychiatry; 1991 Sep; 159():319-24. PubMed ID: 1683592
    [No Abstract]   [Full Text] [Related]  

  • 19. Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes.
    Joyce JN; Goldsmith SG; Gurevich EV
    J Psychiatr Res; 1997; 31(2):197-217. PubMed ID: 9278186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
    Stahl SM; Shayegan DK
    J Clin Psychiatry; 2003; 64 Suppl 19():6-12. PubMed ID: 14728084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.